GI Oncology

Expert-led videos and podcasts reviewing newly approved therapies in gastrointestinal (GI) cancers, with discussion of clinical trial data and implications for patient management across GI malignancies.

GI Oncology

OncUpdates article on Zanidatamab combinations approved for HER2+ gastroesophageal cancers featuring Dr. Natalya Uboha, Dr. Rahul Gosain, and Dr. Rohit Gosain.

GI Oncology

08/27/2026

Zanidatamab Combinations Approved for HER2+ Gastroesophageal Cancers

Nataliya Uboha, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD

1. Durvalumab approved for resectable upper gastrointestinal cancers with expert oncologists discussing treatment options.

GI Oncology

12/03/2025

Durvalumab Approved For Resectable Upper Gastrointestinal Cancers

Yelena Janjigian, MDRahul Gosain, MD, MBARohit Gosain, MD

Group photo of three doctors, including Dr. Tian Zhang, discussing FDA approval of Cabozantinib for neuroendocrine tumors.

GI Oncology

05/16/2025

FDA Approval of Cabozantinib in Neuroendocrine Tumors

Aman Chauhan, MD